Economists hope they can attract billions of dollars for drug R&D by securitizing research projects. Could they close the innovation gap in the process?
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mullard, A. Economists propose a US$30 billion boost to biomedical R&D. Nat Rev Drug Discov 11, 735–737 (2012). https://doi.org/10.1038/nrd3857
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd3857
